Scientists discover powerful potential pain reliever

August 16, 2017, University of Texas at Austin
Stephen Martin (left) and James Sahn have discovered a new pain reliever that acts on a previously unknown pain pathway. Credit: Stephen Martin

A team of scientists led by chemists Stephen Martin and James Sahn at The University of Texas at Austin have discovered what they say is a powerful pain reliever that acts on a previously unknown pain pathway. The synthetic compound, known as UKH-1114, is as effective at relieving neuropathic pain in injured mice as a drug widely used for pain relief called gabapentin, but it works at a much lower dose, with longer duration of action.

If the researchers can demonstrate that the drug is safe, effective and nonaddictive in humans—a process that typically takes years—the discovery could be instrumental in addressing one of today's biggest public health challenges: the opioid abuse epidemic.

Nearly a third of Americans suffer from chronic pain, yet the most effective pain relievers—opioids—are addictive and often require increased dosing to maintain efficacy. According to the National Institute on Drug Abuse, about 2 million people in the U.S. suffer from addiction to prescription opioid pain relievers. Alternatives to opioids have their own drawbacks—for example, gabapentin (sold as Neurontin) can cause cognitive impairment in certain individuals.

"This opens the door to having a new treatment for neuropathic pain that is not an opioid," said Martin, a professor and the M. June and J. Virgil Waggoner Regents Chair in Chemistry. "And that has huge implications."

The pain drug they found binds to a receptor on cells throughout the central nervous system called the sigma 2 receptor. Although it was discovered 25 years ago, scientists still did not know what sigma 2 did until now.

Theodore Price, associate professor of neuroscience at The University of Texas at Dallas and a leading expert on chronic pain, tested UKH-1114 on mice with nerve damage and found that it alleviated pain as well as gabapentin did, but at a much lower dose (one-sixth as much) and was effective much longer (lasting for a couple of days, compared with 4 to 6 hours). This research is the first to demonstrate that the sigma 2 receptor may be a target for treating neuropathic pain.

Results are published in the Aug. 18 print edition of the journal ACS Chemical Neuroscience. An earlier paper, published online on May 28 in the journal Proceedings of the National Academy of Sciences, described the molecular cloning and identification of the sigma 2 receptor.

The researchers have filed patent applications on the new compound.

Neuropathic , or , is caused when nerves in the central nervous system are damaged. Among other things, it can result from chemotherapy, diabetes and injuries to the brain or spinal cord.

Much work remains to be done before UKH-1114 can enter the market. More studies are needed to demonstrate safety, efficacy and oral bioavailability. In the meantime, the scientists are working to understand, on a fundamental level, how activating the sigma 2 receptor relieves .

Still, Martin and Sahn are excited by the compelling results from the mouse model.

"We started out just working on fundamental chemistry in the lab," said Sahn, a research scientist in the Department of Chemistry. "But now we see the possibility that our discoveries could improve the quality of people's lives. That is very satisfying."

Explore further: Are clinicians overprescribing gabapentinoids for pain?

More information: James J. Sahn et al, Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice, ACS Chemical Neuroscience (2017). DOI: 10.1021/acschemneuro.7b00200

Assaf Alon et al. Identification of the gene that codes for the σ2receptor, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1705154114

Related Stories

Are clinicians overprescribing gabapentinoids for pain?

August 3, 2017
(HealthDay)—Clinicians may be overprescribing gabapentinoids, in part as a response to the opioid epidemic, according to a perspective piece published in the Aug. 3 issue of the New England Journal of Medicine.

Scientists discover new category of analgesic drugs that may treat neuropathic pain

March 29, 2017
New research published online in The FASEB Journal suggests that a novel therapeutic target called LPCAT2 may prove effective against pain that is not receptive to the current treatments. This study has also revealed the ...

Potential drug for treating chronic pain with few side effects

July 31, 2017
Researchers at Okayama University describe in the Proceedings of the National Academy of Sciences the effect of clodronate on the regulation of adenosine triphosphate release and its potential as a drug for the treatment ...

Investigators examine the relationship between pain and opioid abuse

June 12, 2017
The drug overdose epidemic is largely driven by opioids, which continue to be prescribed for chronic pain despite recommendations to use non-opioids for most cases. A new review published in the British Journal of Pharmacology ...

Targeting brain cells to alleviate neuropathic pain

August 8, 2016
Neuropathic pain – which affects more than 1 million Americans – could be reduced or even eliminated by targeting brain cells that are supposed to provide immunity but, in some instances, do the opposite, causing chronic ...

Recommended for you

Mechanisms of harmful overhydration and brain swelling

May 22, 2018
We are all familiar with the drawbacks of dehydration, but we rarely hear about the harmful effects of overhydration. For one, excess fluid accumulation can lead to dangerously low sodium levels in the blood or hyponatremia—a ...

Mice brain structure linked with sex-based differences in anxiety behavior

May 22, 2018
Using male individuals has long been a tradition in scientific mice studies. But new research enforces the importance of using a balanced population of male and female mice.

Cell types underlying schizophrenia identified

May 22, 2018
Scientists at Karolinska Institutet in Sweden and University of North Carolina have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development ...

In brain stimulation therapy less might be more

May 22, 2018
One of the promising non-invasive brain therapeutic methods is the repetitive transcranial magnetic stimulation (rTMS). During such a procedure, a magnetic coil is placed near the head of the patient and a magnetic pulse ...

Subtle hearing loss while young changes brain function, study finds

May 22, 2018
Cranking up your headphones or scrambling for a front-row spot at rock shows could be damaging more than your hearing.

What helps form long-term memory also drives the development of neurodegenerative disease

May 22, 2018
Scientists have just discovered that a small region of a cellular protein that helps long-term memories form also drives the neurodegeneration seen in Amyotrophic Lateral Sclerosis (ALS). This small part of the Ataxin-2 protein ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

jdman
not rated yet Aug 21, 2017
Need some test subjects?
SKULLTRAP
not rated yet Aug 21, 2017
If this new drug cannot produce a euphoric state, shut the research down. Waste of time & $$.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.